Dexrazoxane (Zinecard)

The (+)-enantiomorph of razoxane.

Also Known As:

Zinecard; ADR-529; Cardioxan; Cardioxane; Dexrazoxane Hydrochloride; ICRF-187; NSC-169780; Razoxane, (S)-Isomer; Razoxane, (S)-Isomer, Hydrochloride; ADR 529; ADR529; Hydrochloride, Dexrazoxane; ICRF 187; ICRF187; NSC 169780; NSC169780

Networked: 493 relevant articles (95 outcomes, 122 trials/studies)

Relationship Network

Drug Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Piperazines: 26
    - Diketopiperazines: 59
      - Razoxane: 164
        Dexrazoxane: 493
        JR-311: 1

Experts

1.	Lipshultz, Steven E: 23 articles (01/2022 - 07/2004)
2.	Hasinoff, Brian B: 12 articles (01/2020 - 01/2002)
3.	Sehested, Maxwell: 12 articles (02/2012 - 06/2002)
4.	Franco, Vivian I: 10 articles (01/2019 - 03/2011)
5.	Jirkovský, Eduard: 8 articles (01/2022 - 03/2013)
6.	Šimůnek, Tomáš: 8 articles (01/2022 - 09/2013)
7.	Štěrba, Martin: 8 articles (01/2022 - 09/2013)
8.	Langer, Seppo W: 8 articles (01/2014 - 08/2003)
9.	Jensen, Peter Buhl: 8 articles (02/2012 - 08/2003)
10.	Adamcová, Michaela: 6 articles (01/2022 - 01/2002)

Related Diseases

1.	Cardiotoxicity 01/01/2004 - "Further research may help to identify those patients who are at particular risk of cardiotoxicity and who would benefit the most from dexrazoxane. " 04/01/2023 - "The efficacy of dexrazoxane has been demonstrated in clinical trials within the pediatric population with roughly 60%-80% reduction in risk of developing cardiotoxicity with a very tolerable and limited side effect profile. " 01/01/1992 - "This finding suggests that significant protection against DXR-induced chronic cardiotoxicity in the rat can be obtained using deferred treatment with ADR-529." 01/01/1994 - "ICRF-187 provided a higher degree of protection against the cardiotoxicity and the mortality induced by DXR. " 01/01/2018 - "Despite increasing cardiotoxicity-free dose by >150 mg/m, dexrazoxane minimally improved projected survival (71.9% vs. 75.4%). "
2.	Neoplasms (Cancer) 01/01/2010 - "Based on the available data, dexrazoxane appears to be a safe and effective cardioprotectant in children, and it does not appear to alter overall survival times in children with cancer. " 01/01/2005 - "At present, the cardioprotective efficacy of dexrazoxane in patients with childhood malignancies is supported by limited data. " 01/01/2022 - "The objective of this study was to examine long-term outcomes among children newly diagnosed with cancer who were treated in dexrazoxane-containing clinical trials. " 01/01/2019 - "This study intended to analyze cardioprotective efficacy and secondary malignancy development, and elucidate risk factors for secondary malignancies in dexrazoxane-treated pediatric patients. " 06/01/2001 - "Phase I trial of 96-hour continuous infusion of dexrazoxane in patients with advanced malignancies."
3.	Breast Neoplasms (Breast Cancer) 01/01/2017 - "Two meta-analyses in metastatic breast cancer have rejected this hypothesis, but have shown an apparent increase in the severity of myelosuppression when dexrazoxane is used. " 09/01/2015 - "SST-2 breast tumor-bearing SHRs were treated with saline, Dox, dexrazoxane (Drz) or both Dox and Drz and monitored for 14 days. " 09/01/1998 - "Although preliminary pharmacoeconomic analyses have shown dexrazoxane to be a cost-effective agent in women with advanced breast cancer, they require confirmation. " 05/01/1995 - "From January 1991 to August 1993, 237 women with metastatic breast cancer were recruited into a multicentric phase II clinical trial designed to assess the cardioprotective activity of Cardioxane (ICRF-187). " 11/01/2008 - "Further trials are required to evaluate the efficacy of dexrazoxane in hematological malignancies as well as the adjuvant treatment of breast cancer. "
4.	Necrosis 08/01/2007 - "However, dexrazoxane has proven highly effective in preventing necrosis in both preclinical and clinical studies and is now approved in Europe (Savene), and has orphan drug status in the USA (Totect) for this indication. " 04/01/2009 - "In two multicenter studies dexrazoxane has proven to be highly effective in preventing skin necrosis and ulceration. " 03/01/2018 - "Dexrazoxane prevents skin necrosis in non-target embolization of falciform artery during transcatheter arterial chemoembolization (TACE)." 02/01/1999 - "Cutaneous and subcutaneous necrosis following dexrazoxane-CHOP therapy." 08/01/2007 - "Data suggest that administration of IV dexrazoxane is effective in preventing tissue necrosis following anthracycline extravasation. "
5.	Cardiomyopathies (Cardiomyopathy) 06/01/2013 - "Because this is paralleled by an improved cardiac performance in cav1 mice, our data suggest dexrazoxane as a novel therapeutic strategy in this specific cardiomyopathy." 01/01/1986 - "The results of the present study demonstrate that pretreatment with ICRF-187 provides prolonged protection against the cardiomyopathy, as opposed to producing only a delay in the appearance of cardiac alterations." 01/01/2020 - "And, despite the early use of dexrazoxane, no effective treatment strategy has emerged to prevent the development of cardiomyopathy, despite decades of study, suggesting that much more insight into the underlying mechanism of the development of cardiomyopathy is needed. " 01/01/2017 - "The cardioprotectant dexrazoxane can be used as prophylaxis to diminish risk for cardiomyopathy but whether it affects risk of relapse in pediatric AML is unclear. " 01/01/2005 - "The cardioprotectant agent dexrazoxane reduces cardiomyopathy but there are significant toxicity issues. "

Related Drugs and Biologics

1.	Anthracyclines
2.	Doxorubicin (Adriamycin)
3.	Dexrazoxane (Zinecard)
4.	Iron
5.	Epirubicin (Ellence)
6.	Type II DNA Topoisomerases (Topoisomerase II)
7.	Cardiotonic Agents (Cardiac Stimulants)
8.	Chelating Agents
9.	Trastuzumab (Herceptin)
10.	Antioxidants

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Therapeutics
3.	Radiotherapy
4.	Remission Induction
5.	Length of Stay